MX384919B - Receptores de células t de kras anti-mutado. - Google Patents

Receptores de células t de kras anti-mutado.

Info

Publication number
MX384919B
MX384919B MX2017006865A MX2017006865A MX384919B MX 384919 B MX384919 B MX 384919B MX 2017006865 A MX2017006865 A MX 2017006865A MX 2017006865 A MX2017006865 A MX 2017006865A MX 384919 B MX384919 B MX 384919B
Authority
MX
Mexico
Prior art keywords
oncogene homolog
kras
mammal
sub
disclosed
Prior art date
Application number
MX2017006865A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006865A (es
Inventor
James C Yang
Qiong J Wang
Zhiya Yu
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2017006865A publication Critical patent/MX2017006865A/es
Publication of MX384919B publication Critical patent/MX384919B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
MX2017006865A 2014-11-26 2015-11-24 Receptores de células t de kras anti-mutado. MX384919B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084654P 2014-11-26 2014-11-26
US201562171321P 2015-06-05 2015-06-05
PCT/US2015/062269 WO2016085904A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Publications (2)

Publication Number Publication Date
MX2017006865A MX2017006865A (es) 2018-01-11
MX384919B true MX384919B (es) 2025-03-14

Family

ID=54838442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006865A MX384919B (es) 2014-11-26 2015-11-24 Receptores de células t de kras anti-mutado.

Country Status (16)

Country Link
US (3) US11207394B2 (enExample)
EP (3) EP3223850B1 (enExample)
JP (2) JP6863893B2 (enExample)
KR (1) KR102622784B1 (enExample)
CN (3) CN113956349B (enExample)
AU (3) AU2015353720B2 (enExample)
ES (2) ES2784261T3 (enExample)
HU (1) HUE065689T2 (enExample)
IL (1) IL252258B (enExample)
MX (1) MX384919B (enExample)
PL (1) PL3223850T3 (enExample)
PT (1) PT3223850T (enExample)
SA (1) SA517381608B1 (enExample)
SG (2) SG10201913978RA (enExample)
SI (1) SI3223850T1 (enExample)
WO (1) WO2016085904A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784261T3 (es) * 2014-11-26 2020-09-23 Us Health Receptores de células T anti-KRAS mutado
ES2879287T3 (es) 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
EP4159751A1 (en) * 2016-08-02 2023-04-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-kras-g12d t cell receptors
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
WO2018208553A1 (en) * 2017-05-12 2018-11-15 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific t cell receptors and uses thereof
AU2018269370B2 (en) * 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
MX2020003117A (es) * 2017-09-20 2020-08-20 Us Health Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
CN111344394A (zh) * 2017-09-29 2020-06-26 美国卫生和人力服务部 分离对p53癌症-特异性突变具有抗原特异性的t细胞的方法
CA3077595A1 (en) 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
US11466071B2 (en) * 2017-12-04 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class I-restricted t cell receptors against mutated RAS
CN110016074B (zh) * 2018-01-08 2021-03-30 中国科学院广州生物医药与健康研究院 Mage-a3人源化t细胞受体
WO2019246286A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2020037239A1 (en) 2018-08-16 2020-02-20 Neon Therapeutics, Inc. T cell receptor constructs and uses thereof
AU2020211922B2 (en) * 2019-01-22 2025-05-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted T cell receptors against RAS with G12R mutation
CA3127673A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
BR112021023794A2 (pt) * 2019-05-27 2022-01-04 Provincial Health Services Authority Agente de direcionamento de antígeno, molécula de ácido nucleico isolada, composição farmacêutica, célula citotóxica, e, métodos para produzir uma célula citotóxica, para realizar uma terapia celular adotiva, para realizar uma imunoterapia e para detectar câncer em um sujeito mamífero
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US12577278B2 (en) * 2019-06-07 2026-03-17 Emory University KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
EP3997131A4 (en) 2019-07-12 2023-08-02 The Regents of the University of California Chemically controlled monoclonal antibody target engagement
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
JP2023502625A (ja) * 2019-11-15 2023-01-25 グリットストーン バイオ インコーポレイテッド 共有新抗原を標的にする抗原結合タンパク質
CU20220044A7 (es) * 2020-02-12 2023-06-13 Us Health Receptor de células t restringido por hla de la clase i contra ras con mutación g12d
BR112022015897A2 (pt) * 2020-02-14 2022-10-18 Us Health Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
WO2021242961A1 (en) * 2020-05-27 2021-12-02 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
CA3185483A1 (en) * 2020-07-16 2022-01-20 Noam LEVIN Hla class ii-restricted drb t cell receptors against ras with g12v mutation
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
AU2021389909A1 (en) * 2020-11-24 2023-06-22 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
CA3212382A1 (en) * 2021-03-19 2022-09-22 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
CN116063511B (zh) * 2021-09-30 2023-10-03 北京可瑞生物科技有限公司 抗原结合蛋白及其应用
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
EP4466283A1 (en) 2022-01-21 2024-11-27 T-Knife GmbH Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114591443A (zh) * 2022-03-07 2022-06-07 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于scTv的嵌合受体CSR及其应用
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024055003A1 (en) * 2022-09-08 2024-03-14 The Regents Of The University Of California Binding agent recognition of drug-peptide conjugates
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
IL322077A (en) * 2023-01-13 2025-09-01 Corregene Biotechnology Co Ltd Antigen-binding protein and its use
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
IL327158A (en) * 2023-09-15 2026-05-01 Funda??O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud T-type receptor against mKRAS7-16 G12V and G12C
WO2025056656A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V
WO2025189363A1 (zh) * 2024-03-12 2025-09-18 广州医科大学 一种t细胞受体(tcr)及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
AU2008206442B2 (en) * 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
ES2784261T3 (es) * 2014-11-26 2020-09-23 Us Health Receptores de células T anti-KRAS mutado
CN105802909B (zh) * 2014-12-31 2021-01-01 中国医学科学院基础医学研究所 具有her2特异性tcr的t细胞制备物及其用途
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
CN113621070A (zh) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用

Also Published As

Publication number Publication date
JP2021104044A (ja) 2021-07-26
EP3223850B1 (en) 2020-01-08
JP7297807B2 (ja) 2023-06-26
AU2015353720A1 (en) 2017-06-08
CA2968399A1 (en) 2016-06-02
HK1243642A1 (en) 2018-07-20
AU2020203465A1 (en) 2020-06-18
KR102622784B1 (ko) 2024-01-09
ES2784261T3 (es) 2020-09-23
US11207394B2 (en) 2021-12-28
US20220088164A1 (en) 2022-03-24
EP4286407B1 (en) 2026-03-18
KR20170099905A (ko) 2017-09-01
EP3666288B1 (en) 2023-09-27
SG11201704155UA (en) 2017-06-29
JP6863893B2 (ja) 2021-04-21
HUE065689T2 (hu) 2024-06-28
AU2023200614B2 (en) 2026-02-26
IL252258B (en) 2021-12-01
ES2965689T3 (es) 2024-04-16
WO2016085904A1 (en) 2016-06-02
US12312391B2 (en) 2025-05-27
EP3223850A1 (en) 2017-10-04
US20250263462A1 (en) 2025-08-21
IL252258A0 (en) 2017-07-31
US20170304421A1 (en) 2017-10-26
NZ732045A (en) 2024-04-26
CN118994363A (zh) 2024-11-22
MX2017006865A (es) 2018-01-11
EP4286407A2 (en) 2023-12-06
EP3666288A1 (en) 2020-06-17
CN113956349B (zh) 2024-09-06
CN113956349A (zh) 2022-01-21
AU2015353720B2 (en) 2020-02-27
AU2020203465B2 (en) 2022-11-17
EP4286407A3 (en) 2024-03-06
PL3223850T3 (pl) 2020-08-24
CN107223134A (zh) 2017-09-29
SG10201913978RA (en) 2020-03-30
AU2023200614A1 (en) 2023-03-09
SA517381608B1 (ar) 2021-03-11
JP2017536825A (ja) 2017-12-14
PT3223850T (pt) 2020-04-13
SI3223850T1 (sl) 2020-09-30
CN107223134B (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
EP4286407A3 (en) Anti-mutated kras t cell receptors
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
MX2024005677A (es) Receptores de celulas t que reconocen p53 mutado.
CR20200287A (es) Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX367279B (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2020009472A (es) Receptores de antigenos quimericos anti-cd33 y sus usos.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
EA202192126A3 (ru) Способы сбора культур клеток млекопитающих
CY1118970T1 (el) Στελεχη shigella με υπερφλυκταινωση
SG10201807572PA (en) Robust antibody purification
NZ732073A (en) Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
IL284803A (en) Methods of producing multimeric proteins in eukaryotic host cells
AR106716A1 (es) Anticuerpos anti-factor d y conjugados